Category Archives: AZBio News

Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19

Posted on by
  • U.S. FDA authorizes COVID-19 mRNA vaccine for emergency use; companies are prepared to deliver first doses in the U.S. immediately
  • Pfizer and BioNTech previously announced an agreement with the U.S. Government to supply doses in 2020 & 2021
    In collaboration with Operation Warp Speed, Pfizer and BioNTech, as well as other vaccine companies are expected to deliver hundreds of millions of vaccine doses to Americans by the end of 2021
  • Historic science-driven efforts will seek to help bring an end to the most devastating pandemic in a century
  • Pfizer and BioNTech expect to file a Biologics License Application for possible full regulatory approval in 2021

Continue reading→

AZBio Celebrates Trailblazers in 2020

Posted on by

Each year, AZBio looks back across the legislative session to identify those leaders whose actions and active engagement support the growth of Arizona’s life science and healthcare industry and help to ensure the people of Arizona benefit from its success.  Scores are then tallied and the top ten legislative leaders are named the year’s Trailblazers.Continue reading→

NIH’s All of Us Research Program returns first genetic results to participants  

Posted on by

The All of Us Research Program offers participants the opportunity to receive information back about their DNA. NIH
The National Institutes of Health’s All of Us Research Program has begun to return genetic results to participants who have donated biosamples for research. This reflects the program’s priority to give back information to its research volunteers. Initially, participants can choose to receive information about their genetic ancestry and traits, with health-related results available at a later date.Continue reading→

HTG Announces an Early Access Program for its Prototype Whole Transcriptome Panel

Posted on by

TUCSON, Ariz., Dec. 08, 2020 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has launched an Early Access Program for its whole transcriptome panel using the HTG EdgeSeq technology. The Early Access Program is intended to allow select customers access to the panel in their laboratories or through services to be performed in our development laboratory prior to commercial launch of this product.Continue reading→

Aqualung Therapeutics Corp. Publication Supports eNAMPT as Both Biomarker & Therapeutic Target in Prostate Cancer; Prostate Cancer KOL New Addition to Scientific Advisory Board

Posted on by

Aqualung Therapeutics, an early-stage biotech company developing an anti-inflammatory therapeutic platform for patients with serious unchecked inflammatory disease, has published proof of concept studies in EBio Medicine suggesting eNAMPT as a potential biomarker for the severity of invasive Prostate Cancer (PCa), and eNAMPT- neutralization as an effective therapeutic approach to limit PCa invasion and progression. Based on these findings, Aqualung has added Edwin M. Posadas MD, FACP to the Scientific Advisory Board.
Continue reading→

BIO Leads Group Challenging Administration’s “Most Favored Nation” Rule

Posted on by

On December 4, 2020, the Biotechnology Innovation Organization (BIO), the California Life Sciences Association (CLSA), and BIOCOM California today filed a challenge against the Department of Health and Human Services’ (HHS) attempt, during the final days of the Trump Administration, to implement for the first time ever a “Most Favored Nation” reimbursement policy for certain drugs administered by Medicare Part B providers – drastically altering this system in ways that will harm their ability to serve America’s most vulnerable senior citizens.Continue reading→